Hib CRM197 vaccine conjugate - Nuron

Drug Profile

Hib CRM197 vaccine conjugate - Nuron

Alternative Names: HibTITER; MT-2301; NU300

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Mitsubishi Tanabe Pharma Corporation; Nuron Biotech; Wyeth
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Haemophilus infections

Most Recent Events

  • 09 Feb 2017 No development reported - Phase-II for Haemophilus infections (In infants, Prevention) in USA (IM)
  • 06 Feb 2017 Discontinued - Phase-II for Haemophilus infections (In infants, Prevention) in Japan (IM) (Mitsubishi Tanabe Pharma pipeline, February 2017)
  • 02 Aug 2016 Phase-II development in Haemophilus infections (In infants, Prevention) is ongoing in Japan (Mitsubishi Tanabe Pharma Pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top